Key result
In subjects with mild hypertension, 2 g/day of NWT-03 significantly reduced daytime systolic blood pressure by 7.9 mmHg compared to placebo, although no dose-response relationship was observed.
Why the study?
Does NWT-03 reduce daytime, 36-h, and night-time blood pressure in normotensive, high-normotensive, and mild-hypertensive adults?
RCT (n=92)
Placebo-controlled
Randomized
No
Does NWT-03 reduce daytime, 36-h, and night-time blood pressure in normotensive, high-normotensive, and mild-hypertensive adults?
NWT-03 egg-protein hydrolysate may lower ambulatory blood pressure in mild hypertension, but the lack of a dose-response relationship requires cautious interpretation.
Supports hypothesis of BP effects from NWT-03 in mild hypertension; leaves open clinical adoption pending larger confirmatory trials.
Angiotensin-converting enzyme (ACE) inhibitors are important agents in blood pressure (BP) management. It was recently shown that the egg-protein hydrolysate NWT-03 inhibited ACE in Zucker diabetic fatty rats. We therefore designed a dose-finding study to assess the effects of 1, 2 and 5 g NWT-03 on daytime, 36-h, and night-time systolic and diastolic BP (SBP and DBP) in ninety-two generally healthy subjects with normal BP (n 29), high-normal BP (n 34) or mild hypertension (n 29). The study had a cross-over design with six treatment arms (1 g NWT-03 or placebo in period 1 and placebo or 1 g NWT-03 in period 2, 2 g NTW-03 or placebo in period 1 and placebo or 2 g NWT-03 in period 2, or 5 g NTW-03 or placebo in period 1 and placebo or 5 g NTW-03 in period 2). A comparable number of subjects from each BP class were included in each study arm. Duration of both treatments in each arm was 7 d, separated by 5-d wash-out periods. BP was measured with an ambulatory BP monitor before and after the treatments. In mild-hypertensive subjects, 2 g NWT-03 significantly decreased daytime SBP (7·9 mmHg; P=0·006), daytime DBP (4·2 mmHg; P=0·009), 36-h SBP (6·9 mmHg; P=0·015) and 36-h DBP (3·5 mmHg; P=0·035) compared with placebo subjects. In addition, in mild-hypertensive subjects, 5 g NWT-03 significantly decreased night-time SBP (14·8 mmHg; P=0·008) and night-time DBP (8·4 mmHg; P=0·020) compared with that in placebo subjects. To conclude, we found that 2 g NWT-03 lowered daytime and 36-h BP in subjects with mild hypertension, and 5 g NWT-03 lowered night-time BP in subjects with mild hypertension. As no dose-response relationship was evident, these results should be interpreted with care, and additional studies are needed.
No takes yet. Share an insight, caveat, or question.
Plat et al. (2017) conducted an RCT in Normal to mild hypertension (n=92). NWT-03 (egg-protein hydrolysate) vs. Placebo was evaluated on Daytime systolic blood pressure in mild-hypertensive subjects (2g dose) (MD -7.9 mmHg, p=0.006). In subjects with mild hypertension, 2 g/day of NWT-03 significantly reduced daytime systolic blood pressure by 7.9 mmHg compared to placebo, although no dose-response relationship was observed.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: